ATE230278T1 - Mri-mittel zum nachweis von physiologischen mitteln - Google Patents

Mri-mittel zum nachweis von physiologischen mitteln

Info

Publication number
ATE230278T1
ATE230278T1 AT96917061T AT96917061T ATE230278T1 AT E230278 T1 ATE230278 T1 AT E230278T1 AT 96917061 T AT96917061 T AT 96917061T AT 96917061 T AT96917061 T AT 96917061T AT E230278 T1 ATE230278 T1 AT E230278T1
Authority
AT
Austria
Prior art keywords
detecting physiological
physiological agents
chelator
metal ion
mri means
Prior art date
Application number
AT96917061T
Other languages
English (en)
Inventor
Thomas Meade
Scott Fraser
Russell Jacobs
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of ATE230278T1 publication Critical patent/ATE230278T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AT96917061T 1995-06-02 1996-06-03 Mri-mittel zum nachweis von physiologischen mitteln ATE230278T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46051195A 1995-06-02 1995-06-02
US08/486,968 US5707605A (en) 1995-06-02 1995-06-07 Magnetic resonance imaging agents for the detection of physiological agents
PCT/US1996/008548 WO1996038184A2 (en) 1995-06-02 1996-06-03 Magnetic resonance imaging agents for the detection of physiological agents

Publications (1)

Publication Number Publication Date
ATE230278T1 true ATE230278T1 (de) 2003-01-15

Family

ID=27039723

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96917061T ATE230278T1 (de) 1995-06-02 1996-06-03 Mri-mittel zum nachweis von physiologischen mitteln

Country Status (10)

Country Link
US (1) US5707605A (de)
EP (1) EP0831928B1 (de)
JP (1) JPH11506455A (de)
AT (1) ATE230278T1 (de)
AU (1) AU712899B2 (de)
CA (1) CA2222974C (de)
DE (1) DE69625595T2 (de)
ES (1) ES2189873T3 (de)
NO (1) NO975517L (de)
WO (1) WO1996038184A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980862A (en) * 1995-06-02 1999-11-09 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US6770261B2 (en) 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
AU726914B2 (en) 1996-04-01 2000-11-23 Epix Pharmaceuticals, Inc. Bioactivated diagnostic imaging contrast agents
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
EP0977598A1 (de) * 1997-04-22 2000-02-09 Nycomed Imaging As Verbindungenfür nmr bildumgebung
ATE381352T1 (de) * 1997-07-01 2008-01-15 Ge Healthcare As Diagnostisches verfahren zum nachweis von myokard-ischämie
DE69811931T2 (de) * 1997-10-27 2003-12-18 Research Corp. Technologies, Inc. Mri-mittel für die verabreichung von therapeutischen mitteln
US6713046B1 (en) 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
US20040170563A1 (en) * 1997-10-27 2004-09-02 Meade Thomas J. Magnetic resonance imaging agents for the delivery of therapeutic agents
AU752812B2 (en) * 1997-11-17 2002-10-03 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
RU2150961C1 (ru) * 1998-02-06 2000-06-20 Кулаков Виктор Николаевич Магнитно-резонансная контрастная композиция
GB9823175D0 (en) * 1998-10-22 1998-12-16 Nycomed Imaging As Compound
TW490454B (en) * 1999-04-23 2002-06-11 Dept Of Health R O C Triaminopentaacetic acid compound and paramagnetic metal complex prepared from using the compound as ligand
AU1791501A (en) * 1999-11-22 2001-06-04 Epix Medical, Inc. Imaging sexual response
WO2001052906A2 (en) * 2000-01-22 2001-07-26 Epix Medical, Inc. Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
US20030082106A1 (en) * 2000-01-22 2003-05-01 Aleksandr Nivorozhkin Magnetic resonance imaging using contrast agents bioactivated by enzymatic cleavage
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
CA2407450A1 (en) * 2000-05-04 2001-11-08 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
WO2001089584A2 (en) * 2000-05-23 2001-11-29 Amersham Health As Contrast agents
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
AU2001276956A1 (en) 2000-07-17 2002-01-30 California Institute Of Technology Macrocyclic mri contrast agents
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
AU2002220082A1 (en) * 2000-10-19 2002-04-29 The General Hospital Corporation Imaging of enzymatic activity
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
NO20015814D0 (no) * 2001-11-28 2001-11-28 Amersham Health As Metallkompleksforbindelser
EP1487460A2 (de) * 2002-02-28 2004-12-22 A & D Bioscience, Inc. Glycuronamide, glycoside und orthoester-glycoside von fluoxetin, analoga und ihre verwendungen
US8084017B2 (en) * 2002-03-07 2011-12-27 Carnegie Mellon University Contrast agents for magnetic resonance imaging and methods related thereto
US7998704B2 (en) * 2002-03-07 2011-08-16 Carnegie Mellon University Methods for magnetic resonance imaging
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
US20050255038A1 (en) * 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20060193781A1 (en) * 2002-06-03 2006-08-31 Christopher Frederickson Magnetic resonance imaging of metal concentrations
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
JP3606280B2 (ja) * 2002-07-16 2005-01-05 日産自動車株式会社 樹脂製チューブ及び燃料系配管用チューブ
US20040022735A1 (en) * 2002-08-02 2004-02-05 Uzgiris Egidijus E Enzyme activated contrast agents
EP1466629A1 (de) 2003-04-11 2004-10-13 BRACCO IMAGING S.p.A. Adducte zwischen NMR Vershibungsreagenzen und Substraten mit austauschbaren Protonen für die "CEST" Anwendung
US20050036947A1 (en) * 2003-08-12 2005-02-17 General Electric Company Target-specific activatable polymeric imaging agents
US20050232866A1 (en) * 2004-03-26 2005-10-20 Alerion Biomedical Inc. Biochemically-activated contrast agents for magnetic resonance imaging
FR2868320B1 (fr) * 2004-03-31 2007-11-02 Centre Nat Rech Scient Cnrse Agent de contraste pour l'imagerie par resonance magnetique
WO2005096789A2 (en) * 2004-04-12 2005-10-20 Georgia Tech Research Corporation Methods and compositions for imaging and biomedical applications
WO2005115105A2 (en) * 2004-05-10 2005-12-08 Northwestern University Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase
JP2008513533A (ja) * 2004-09-23 2008-05-01 ゲルベ Ｃｅｓｔイメージング用の造影剤封入システム
CA2625196C (fr) * 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8003078B2 (en) * 2006-03-29 2011-08-23 Barnes-Jewish Hospital Targeted MR imaging agents
US20090142273A1 (en) * 2006-06-08 2009-06-04 Case Western Reserve University Activatable cest MRI agent
US8133474B2 (en) * 2006-09-15 2012-03-13 Massachusetts Institute Of Technology Sensors for fluorescence and magnetic resonance imaging
US20110135575A1 (en) * 2007-08-28 2011-06-09 Massachusetts Institute Of Technology Metalloprotein mri contrast agents and related methods
US8337813B2 (en) * 2007-09-14 2012-12-25 Northwestern University Contrast agents
US20100029909A1 (en) * 2008-05-23 2010-02-04 Northwestern University Compositions and methods comprising magnetic resonance contrast agents
US8580231B2 (en) 2008-05-23 2013-11-12 Northwestern University Compositions and methods comprising magnetic resonance contrast agents
US20110200525A1 (en) * 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
RU2396983C1 (ru) * 2009-04-13 2010-08-20 Виктор Сергеевич Скуридин Контрастная композиция для медицинской диагностики на основе комплексов гадолиния
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
PL2721045T3 (pl) 2011-06-20 2017-11-30 Radiomedix Inc. Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
ES2830392T3 (es) 2014-07-23 2021-06-03 Ohio State Innovation Foundation Métodos y composiciones relacionados con fragmentos de anticuerpo que se unen a la glicoproteína 72 asociada a tumores (TAG-72)
EP3101012A1 (de) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Neue gadoliniumchelat-verbindung zur verwendung in der magnetresonanzbildgebung
EP3544964B1 (de) 2016-11-28 2020-06-17 Bayer Pharma Aktiengesellschaft Gadolinium-chelat-verbindung mit hoher relaxivität zur verwendung in der magnetresonanzbildgebung
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
IL321215B2 (en) 2018-11-23 2026-05-01 Bayer Ag Contrast media formulation and process for its preparation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188816A (en) * 1984-10-18 1993-02-23 Board Of Regents, The University Of Texas System Using polyazamacrocyclic compounds for intracellular measurement of metal ions using MRS
WO1987002893A1 (en) * 1985-11-18 1987-05-21 Board Of Regents, The University Of Texas System Polychelating agents for image and spectral enhancement (and spectral shift)
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5219553A (en) * 1986-08-04 1993-06-15 Salutar, Inc. Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US5531978A (en) * 1987-07-16 1996-07-02 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
DE3855239T2 (de) * 1987-07-16 1996-10-31 Nycomed Imaging As Aminocarbonsäure und Derivate
US5554748A (en) * 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
US5087440A (en) * 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
US5446145A (en) * 1990-01-19 1995-08-29 Nycomed Salutar, Inc. Polychelant compounds
EP0511275A1 (de) * 1990-01-19 1992-11-04 Nycomed Imaging As Komplexbildner
WO1992019264A1 (en) * 1991-05-01 1992-11-12 University Of New Mexico Biomodulators as universal imaging agents
US5262532A (en) * 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US5407657A (en) * 1992-09-22 1995-04-18 Unger; Evan C. Hybrid magnetic resonance contrast agents
US5466439A (en) * 1992-11-12 1995-11-14 Magnetic Research, Inc. Polymeric contrast enhancing agents for magnetic resonance images
US5358704A (en) * 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents

Also Published As

Publication number Publication date
AU712899B2 (en) 1999-11-18
WO1996038184A3 (en) 1997-03-13
DE69625595T2 (de) 2003-11-27
US5707605A (en) 1998-01-13
CA2222974A1 (en) 1996-12-05
EP0831928A2 (de) 1998-04-01
ES2189873T3 (es) 2003-07-16
NO975517L (no) 1998-01-19
WO1996038184A2 (en) 1996-12-05
DE69625595D1 (de) 2003-02-06
EP0831928B1 (de) 2003-01-02
JPH11506455A (ja) 1999-06-08
NO975517D0 (no) 1997-12-01
AU5975196A (en) 1996-12-18
CA2222974C (en) 2004-05-11

Similar Documents

Publication Publication Date Title
DE69625595D1 (de) Mri-mittel zum nachweis von physiologischen mitteln
PL336299A1 (en) Application of unidimensional magnetic nuclear resonance for identifying ligands of target biological molecules
EP0612240A4 (de) Verfahren zur verlängerung der vaskulären verweildauer von partikelförmigen therapeutischen und diagnostischen wirkstoffen.
DE69631575D1 (de) Abgeschirmter und offener Magnet für die Bilderzeugung durch magnetische Resonanz
HUP0104715A3 (en) Blood pool agents for nuclear magnetic resonance diagnostics
DE69631408D1 (de) Medizinische Vorrichtung sichtbar während des Gebrauchs einer magnetischen Resonanz-Bilderzeugung
ATE138809T1 (de) Anwendung von chelat-komplexen
ATE136302T1 (de) Makrozyklische tetraaza-verbindungen
MX9709913A (es) Metaloconstrucciones determinadas estructuralmente y aplicaciones.
ITSV970048A0 (it) Magnete permanente per il rilevamento d'immagini in risonaza magnetica nucleare.
ATE254631T1 (de) Pretargeting verfahren und mitteln
AU2693195A (en) Emulsions of paramagnetic contrast agents for magnetic resonance imaging (mri), containing an organic chelator having an unsaturated aliphatic group
FR2645954B1 (fr) Procede de determination d'une position utilisant des satellites
IT1317862B1 (it) Coniugati di acidi biliari con chelati complessi di ioni metallici eloro uso.
FR2771297B1 (fr) Sonde bicanaliculaire pour le traitement du larmoiement de l'oeil
NL970040I1 (nl) Dipyridoxylfosfaten als contrastmiddelen bij de beeldvorming door kernmagnetische resonantie.
DE59108370D1 (de) Vorrichtung für den Antrieb der Magnetanordnung eines planaren Magnetron für eine Sputteranlage
IT1305960B1 (it) Struttura di magnete in particolare per macchine per il rilevamentod'immagine in risonanza magnetica nucleare.
NO307214B1 (no) Makrosykliske chelanter, deres chelater og anvendelse derav innen det diagnostiske felt
FR2763600B1 (fr) Procede de detection qualitative et quantitative d'alterations de l'adn et des ligands de ces alterations
DE69100842D1 (de) Unlösliche salze von lanthaniden zur bildlichen darstellung des magen-darmtrakts mittels nuklearmagnetischer resonanz.
IT1276143B1 (it) Magnete di selezione degli aghi
BG94960A (bg) Душов метод за вагинално лечение с прилагане на вагинален душ и магнитно кранче
FR2735865B1 (fr) Dispositif d'analyse quantitative par resonance magnetique nucleaire
ITMI932541A0 (it) Chelati paramagnetici per diagnosi in risonanza magnetica nucleare

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0831928

Country of ref document: EP

REN Ceased due to non-payment of the annual fee